IV ferric carboxymaltose vs oral iron
Number of responders ‐ mild to moderate disease (12 weeks) · IBD patients
IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 1.17 [0.95, 1.43]1 study · 200 participantsLow